Entrada Therapeutics (TRDA) Current Assets (2020 - 2026)

Entrada Therapeutics has reported Current Assets for 7 years, with the latest figure at $266.9 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 33.81% year-over-year to $266.9 million; the trailing twelve-month figure through Mar 2026 stood at $266.9 million (down 33.81% YoY), and the FY2025 full-year result was $306.3 million, down 30.4% from the prior year.
• Current Assets for Q1 2026 stood at $266.9 million, down from $306.3 million in the prior quarter.
• The five-year high for Current Assets was $489.5 million in Q2 2024, with the low at $209.9 million in Q4 2022.
• Average Current Assets over 5 years is $355.4 million, with a median of $369.8 million recorded in 2023.
• Year-over-year, Current Assets soared 90.03% in 2022 and plunged 33.81% in 2026.
• Tracing TRDA's Current Assets over 5 years: stood at $209.9 million in 2022, then jumped by 76.19% to $369.8 million in 2023, then gained by 19.0% to $440.0 million in 2024, then plunged by 30.4% to $306.3 million in 2025, then dropped by 12.86% to $266.9 million in 2026.
• The last three Current Assets figures came in at $266.9 million (Q1 2026), $306.3 million (Q4 2025), and $338.3 million (Q3 2025), per Business Quant data.

Peer Comparison